MENU
CHRS
AS OF
Dec 12 closing price
Price
$1.35
Change
-$0.08 (-5.59%)
Capitalization
163.18M
94 days until earnings call
Intraday BUY SELL Signals
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2025 All rights reserved. Tickeron Inc.
CHRS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Coherus Oncology (CHRS) Ownership - Who owns Coherus Oncology?

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers... Show more

Industry: #Biotechnology
#MovingAverage#Momentum#MACD#Pattern#RSI#Stochastic#Aroon#Bollinger

Profile

Industry
Biotechnology
Address
333 Twin Dolphin Drive
Phone
+1 650 649-3530
Employees
306
Web
https://www.coherus.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
163.18M
P/E Ratio
2.45
Total Cash
191.66M
Projected Growth
N/A
Total Debt
40.69M
Revenue
277.73M
Risk (Beta)
1.49
Dividend Yield
N/A
Total Cash/Share
1.59
Total Debt/Equity
N/A
Revenue/Share
2.39 USD as % of share price

Fundamentals

CHRS
Capitalization
163M
P/E Ratio
2.45
Risk (Beta)
1.49
Dividend Yield
N/A
Total Cash
192M
Total Cash/Share
1.59
Total Debt
40.7M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
2.39%
Revenue
278M
ROE
N/A
Book Value
87.8M
P/B Ratio
1.86
Cash Flow
N/A
Earnings
1.33
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
12K
Current Ratio
1.23
Current Revenue Per Employee
71869.56
Dividends Per Share - Security
N/A
EBITDA
90.2M
Float
N/A
Float - Current
N/A
Gross Income Margin
67.84
Revenue To Assets
30.34
Shares Held By Institutions
114M
Shares Outstanding - Current
121M
Total Liabilities
429M
Total Volume MTD
N/A
Value
N/A
Gain YTD
3.623
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
CHRS
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CHRS showed earnings on November 06, 2025. You can read more about the earnings report here.
View AI-Driven Trading for CHRS
A.I. Advisor
published General Information

General Information

a maker of biologic therapeutics for oncology and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
333 Twin Dolphin Drive
Phone
+1 650 649-3530
Employees
306
Web
https://www.coherus.com